This can occur during the initial stages of treatment as your body adjusts to the medication
This new class of medications, known as GP1-inhibitors, is rapidly growing to be a leading solution for weight management
The treatment policy or strategy estimand is used for confirmatory, multiplicity-controlled statistical evaluations
Shaking is catastrophic for peptide integrity
A 2025 narrative review by Varughese and colleagues describes the broader animal-data picture for GLP-1 receptor agonists: decreased fetal weight, delayed bone formation, skeletal variants, and visceral abnormalities in animals exposed during gestation
Weight reduction: In the phase 2 trial, cagrilintide 4.5 mg weekly produced approximately 10.8% body weight loss over 26 weeks versus 3.0% with placebo [4]